MoonLake Immunotherapeutics MLTX Return on equity

Return on equity at other companies

Eli LillyLLY

102.4%+15.7pp

Oruka Therapeutics, Inc.ORKA

-27.3%-11.1pp

Shattuck Labs, Inc.STTK

-61%-8.0pp

Alumis Inc.ALMS

-64.6%—

Upstream Bio, Inc.UPB

-41.8%—

Kymera TherapeuticsKYMR

-24.2%-5.2pp

FAQ

What is MoonLake Immunotherapeutics's return on equity?

MoonLake Immunotherapeutics (MLTX) reported return on equity of -77.7% in Q1 2026.

How has MoonLake Immunotherapeutics's return on equity changed year-over-year?

MoonLake Immunotherapeutics's return on equity decreased by 154.3% year-over-year, from -30.6% to -77.7%.

What is the long-term trend for MoonLake Immunotherapeutics's return on equity?

Over 2 years (2023 to 2025), MoonLake Immunotherapeutics's return on equity has grown at a 113.9% compound annual growth rate (CAGR), from -13.2% to -60.5%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.